Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 1202-1206, March 1, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reiners, J. J.
Right arrow Articles by Pavone, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reiners, J. J., Jr.
Right arrow Articles by Pavone, A.

Tumor Copromoting Activity of {gamma}-Interferon in the Murine Skin Multistage Carcinogenesis Model1

John J. Reiners, Jr.2, Tim Rupp, Alan Colby, Amador R. Cantu and Amy Pavone

The University of Texas M. D. Anderson Cancer Center, Science Park—Research Division, Smithville, Texas 78957

Recombinant DNA-derived murine {gamma}-interferon (rMuIFN-{gamma}) was tested in the murine skin multistage carcinogenesis model as a modulator of 12-O-tetradecanoylphorbol-13-acetate (TPA) promotion. Female SENCAR mice were topically initiated with 7,12-dimethylbenz(a)anthracene and promoted twice weekly with TPA for 20 weeks. Intraperitoneal administration of rMuIFN-{gamma} 1 day prior to TPA treatment affected neither the kinetics of papilloma development nor the percentage of mice that developed tumors. However, papilloma multiplicities could be either inhibited or increased depending upon the dose of rMuIFN-{gamma}. Papilloma multiplicities for mice receiving 100, 500, 1000, and 5000 units of rMuIFN-{gamma} were 184, 122, 105, and 84% of TPA control values, respectively. In contrast, twice weekly i.p. treatments of 7,12-dimethylbenz(a)anthracene initiated mice with only rMuIFN-{gamma} for 20 weeks did not promote the development of any tumors. Consequently, TPA functioned as a copromoter in those situations in which combined TPA and IFN-{gamma} treatments elevated papilloma multiplicities. Collectively, the current study demonstrates that rMuIFN-{gamma} can systemically modulate TPA-dependent promotion in mouse skin.

1 This project was supported by National Cancer Institute Grants CA-40823 and CA-34469 (DHHS) and American Cancer Society Grant IFN-16.

2 To whom requests for reprints should be addressed.

Received 8/15/88. Revised 11/28/88. Accepted 12/ 2/88.




This article has been cited by other articles:


Home page
Cancer Res.Home page
H. J. Halpern, G. V. R. Chandramouli, E. D. Barth, Cheng Yu, Miroslav Peric, D. J. Grdina, and B. A. Teicher
Diminished Aqueous Microviscosity of Tumors in Murine Models Measured with in Vivo Radiofrequency Electron Paramagnetic Resonance
Cancer Res., November 1, 1999; 59(22): 5836 - 5841.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.